LongBURSep 2026
Burford Capital Limited
Burford is the dominant litigation-finance platform, with a large historical case dataset that Greenhaven believes improves case selection and underwriting. More than 285 funded…
Greenhaven Road Investment Management, LP
Concentrated long-biased public-equity investing focused on advantaged businesses, differentiated research and non-consensus views, increasingly paired with identifiable catalysts.$299M AUM10 published ideas
Greenhaven Road Capital invests in businesses where its fundamental conclusions differ meaningfully from market consensus. The manager emphasizes deep primary research, concentrated positions and long-term business quality, while recently moving toward somewhat lower concentration and a greater emphasis on identifiable near-term catalysts.
Ideas from Greenhaven Road Investment Management, LP
LongHGTYSep 2026
Hagerty, Inc.
Hagerty's collectible-car insurance franchise benefits from strong customer loyalty, proprietary data, scale and unusually efficient distribution partnerships. Revenue compounded…
LongCLBTSep 2026
Cellebrite DI Ltd.
The market increasingly treats Cellebrite as vulnerable to AI disruption, while Greenhaven believes AI can expand the company's opportunity. Cellebrite's Genesis product embeds…
LongLFCRSep 2026
Lifecore Biomedical, Inc.
Greenhaven's thesis centers on monetizing Lifecore's excess pharmaceutical manufacturing capacity. The company added seven customers in nine months, including at least two that…
LongKWYSep 2026
Kingsway Corporation
Kingsway is evolving from a neglected conglomerate into a public-market version of the search-fund model. Insider ownership is high, sell-side coverage is absent and Greenhaven…
LongPARSep 2026
PAR Technology Corporation
Greenhaven continues to see a long growth runway for PAR and believes the business has crossed into EBITDA profitability. The fund's differentiated view is that analysts…
LongKKRSep 2026
KKR & Co. Inc.
Greenhaven continues to regard KKR as a high-quality alternative-asset manager despite concerns surrounding private credit. The fund expects the current private-credit scare to…
LongCODISep 2026
Compass Diversified
Compass Diversified became a special-situations investment after fraud at one subsidiary damaged confidence, complicated financial reporting and increased balance-sheet pressure…
LongAPPSep 2026
AppLovin Corporation
Greenhaven initiated a roughly 1% position in AppLovin as part of a small basket of AI beneficiaries. The fund views AppLovin as one of the strongest examples of AI being…
LongANABSep 2026
AnaptysBio, Inc.
AnaptysBio's value is heavily tied to royalties from GSK's Jemperli, which has grown into a strategically important oncology asset with more than $1 billion of sales. Greenhaven…
Letters covered
- July 2026 Investor LetterSeptember 2, 2026
Source PDFs are not republished here; only extracted ideas and quotes.